Biographical Sketch
Joseph Foss, MD, is the Director of Clinical Research for General Anesthesiology in the Department of Anesthesiology at Cleveland clinic’s main campus. His specialty interests include clinical research, pain research, and clinical pharmacology, general and ambulatory anesthesia.
Dr. Foss earned his medical degree from Brown University School of Medicine in Providence, R.I. He completed a surgical internship at the University of Oregon Health Sciences Center in Portland, Ore. He also completed an anesthesia residency and a clinical pharmacology fellowship at the University of Chicago Hospitals in Chicago, Ill.
He is a Diplomate with the American Board of Anesthesiology, and a member of several medical societies, including the American Medical Association, the Ohio Society of Anesthesiologists, the American Society of Anesthesiologists and the International Anesthesia Research Society, among others.
Dr. Foss has published a number of articles in peer-reviewed journals on various topics related to anesthesiology and pharmacology. He has also lectured on the topics.
Specialty Interests
clinical pharmacology, clinical research, general and ambulatory anesthesia, general anesthesia, pain research
Innovations & Patents
Developed a novel drug, methylnaltrexone, which is under FDA review for the treatment of side effects of opioid pain medications.
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 9/4/2008, Dr.
Foss has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Foss receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
Eisai Medical Research Inc.
Royalty Payments. Dr. Foss has the right to receive royalty payments for inventions or discoveries related to the companies shown below:
Progenics, Inc.
Equity. Dr. Foss owns stock or stock options in the following companies for activities as a founder, inventor, or consultant:
Baxter Healthcare Corporation
Cardinal Health, Inc.
Progenics, Inc.
